Pat Mackin, CEO, Artivion : Yeah, I'll come in on the data and I'll let Lance talk about the relationship. Nexus is, and you know, interesting, all the technologies we're talking about from AMDS to Arsivo to Nexus, these are all used in the arch. It's a cutting-edge area, if you will. It's really nascent. We've really, as a company, that's been our focus, is really the cutting-edge technology into the aortic arch. We're a leader in that space. Nexus is a catheter delivery. Both AMDS and Arsivo are done in open surgery under direct vision where you're putting a stent into the aorta. Nexus is a catheter, fully catheter delivered from the groin. The current generation that we're bringing to the U.S., or the first generation, is a branch in the first branch, which is the innominate. That trial has completed. The 30-day data was presented in May.